Citation Impact
Citing Papers
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
2009
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
2009
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study
2004
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
2008 Standout
Lung Cancer in Octogenarians
2010
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration
1989
Lung Cancer
2008 Standout
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Nutrition and physical activity guidelines for cancer survivors
2012 Standout
Lung Cancer: Epidemiology, Etiology, and Prevention
2011 Standout
Oxaliplatin in First-line Therapy for Advanced Non–Small-Cell Lung Cancer
2010
Molecular mechanisms of cisplatin resistance
2011 Standout
Chemotherapy and the war on cancer
2005 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study)
2010
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Free radicals and antioxidants in chemotherapyinduced toxicity
1997
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Docetaxel-related side effects and their management
2009
Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel
2005
Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy
1984
A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: A randomized, double-blind study
1990
Nanoparticles for photothermal therapies
2014 Standout
Etiology and treatment of the psychological side effects associated with cancer chemotherapy: A critical review and discussion.
1988
Peptide-induced emesis in dogs
1984
Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer
2006
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
2008
Complementary/Alternative Medicine Use in a Comprehensive Cancer Center and the Implications for Oncology
2000 Standout
NCCN Task Force Report: Management of Neuropathy in Cancer
2009
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide.
1984
Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial
2012
Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2
2013
The National Cancer Chemotherapy Program
1982 Science
The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy
1985
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
The Pharmacology and Clinical Effectiveness of Phenothiazines and Related Drugs for Managing Chemotherapy-induced Emesis
1983
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study.
1984
Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel
2005
Double‐Blind Multiple‐Dose Crossover Study of the Antiemetic Effect of Intramuscular Levonantradol Compared to Prochlorperazine
1984
Metoclopramide
1983
Cannabinoids for Medical Use
2015 Standout
Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer
2006
Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment.
1984
HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.
1994 StandoutNobel
Behavioral Treatment for the Anticipatory Nausea and Vomiting Induced by Cancer Chemotherapy
1982
Intravenous metoclopramide: Prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation
1984
Cisplatin
1984 Standout
Works of L. Seigel being referenced
Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2
2008
A Randomized Phase II Trial of Two Schedules of Docetaxel in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung Cancer
2007
Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma
2001
Efficacy and Safety of Oxaliplatin and Gemcitabine with Bevacizumab in Advanced Non-small Cell Lung Cancer
2008
The Control of Chemotherapy-Induced Emesis
1981
A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC)
2004
A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC)
2004